Oneness Biotech Co., LTD. receives a Russian patent titled"TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code:ON101).	2021-07-21
	Oneness announces the information about the investor's conference of 2021 Q2.	2021-06-23
	Oneness Bio will hold the launch event and the medical symposium of Fespixon, the new drug for treating DFUs	2021-06-16
	Oneness Biotech and Taiwan CDE signed the agreement of regulatory science consultation and guidance on an indicator project in COVID-19 for FB704A.	2021-06-10
	An IND was submitted to US FDA for a phase II clinical trial of FB704A, an anti-IL6 mAb developed by Oneness, for treating severe COVID-19.	2021-06-08
	The Phase 3 international MRCT study results of the diabetic foot ulcer new drug, Fespixon have been accepted for oral presentation at the 57th EASD Annual Meeting	2021-06-03